AI Terminal
RaySearch Laboratories
Interim / Quarterly Report • May 18, 2022
3101_10-q_2022-05-18_128dcac7-c95f-4f68-b355-2d21ee041d0f.pdf
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
INTERIM REPORT JANUARY 1-MARCH 31, 2022
"In the first quarter of 2022, license revenue rose 35 percent and support revenue rose 24 percent. Operating profit amounted to SEK 30 M (12)."
Johan Löf, CEO of RaySearch
FIRST QUARTER (JANUARY – MARCH 2022)
- Order intake SEK 272.5 M (145.1)
- Net sales SEK 208.1 M (162.1)
- Operating profit SEK 29.6 M (12.3)
- Profit after tax SEK 19.3 M (7.1)
- Earnings per share before/after dilution SEK 0.56 (0.21)
- Cash flow SEK 35.3 M (32.8)
- Order backlog SEK 1,488.7 M (1,207.1) at the end of the period
SIGNIFICANT EVENTS DURING THE FIRST QUARTER
- In January, RaySearch signed an agreement with Proton International Arkansas to provide RayStation at the UAMS Radiation Oncology Center.
- In February, the Charles-Le Moyne hospital in Canada placed an order for RayStation, which will become the hospital's primary treatment planning system.
THE COVID-19 PANDEMIC
The negative effect of the pandemic on RaySearch's sales appears to be weakening as the pandemic subsides. In Asia, market conditions normalized and conditions improved in Europe and the US during the quarter. However, it remains difficult to say how the pandemic will affect the coming quarters with any great certainty.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
- In April, Hong Kong Sanatorium & Hospital placed an order for RayStation, thereby becoming RaySearch's first customer in Hong Kong within the proton therapy segment.
- In April, Seoul National University Hospital placed an order for RayStation.
- In April, Mevion China placed an order for RayStation, which it sold together with Mevion's proton therapy system to Tongji Hospital in Wuhan in China.
- In May, RaySearch entered into an agreement with GE Healthcare to develop a new radiation therapy simulation and treatment planning workflow solution.
- In May, RayCare was taken into clinical use with Accuray's CyberKnife treatment delivery system at Swiss Medical Network in Switzerland.
- CFO Torbjörn Wingårdh left RaySearch.
FINANCIAL SUMMARY1
| AMOUNTS IN SEK 000s | JAN-MAR | APR 2021- | FULL-YEAR | ||
|---|---|---|---|---|---|
| 2022 | 2021 | MAR 2022 | 2021 | ||
| Net sales | 208,149 | 162,102 | 687,720 | 641,673 | |
| Operating profit/loss | 29,564 | 12,261 | -36,038 | -53,341 | |
| Operating margin, % | 14.2 | 7.6 | -5.2 | -8.3 | |
| Profit/loss for the period | 19,298 | 7,110 | -35,127 | -47,315 | |
| Earnings/loss per share before/after dilution, SEK | 0.56 | 0.21 | -1.02 | -1.38 | |
| Cash flow from operating activities | 125,787 | 104,332 | 259,617 | 238,162 | |
| Cash flow for the period | 35,320 | 32,840 | -69,223 | -71,703 | |
| Return on equity, % | 2.9 | 1.0 | -5.3 | -7.3 | |
| Equity/assets ratio, %, at the end of the period | 38.9 | 52.7 | 38.9 | 37.3 | |
| Share price at the end of the period, SEK | 51.7 | 89.5 | 51.7 | 56.5 |
1 For definitions of key ratios, see page 20.
behind us.
CEO COMMENTS
HIGHEST EVER FIRST QUARTER SALES
The pandemic had a negative impact on our sales, but we could see clear signs of a recovery already in the fourth quarter of 2021 and are delighted to note that this positive trend has continued. During the year's first quarter, we witnessed an increase in order intake of 88 percent compared with the year-on-year period and RaySearch's sales were at the highest ever level for a first quarter, SEK 208 M. In addition, EBIT totaled SEK 30 M, representing an operating margin of 14 percent. We also had more opportunities to meet customers faceto-face as travel restrictions were lifted in many countries. The positive signals are in line with our expectations and I am optimistic about a stabilization in market conditions and a return to normal circumstances, even though the pandemic is not yet completely
A few days ago, we returned from one of our industry's main trade fairs, ESTRO, which was a highly positive experience. There was a palpable energy among the many visitors to our booth and great interest in our products, with many demonstrations and a large number of fruitful partnership discussions.
NEW ORDERS STRENGTHEN LEADING POSITION IN PROTON MARKET
Treatment planning for particle treatments (protons/carbon ions/BNCT) is an important focus area for RaySearch and today RayStation has a global market share of more than 60 percent. This position was also strengthened by several important orders, including from Hong Kong Sanatorium & Hospital, Seoul National University Hospital (SNUH) and Proton International Arkansas. Another important order, though not in proton therapy, was from Charles-Le Moyne in Canada. The hospital's cancer clinic has used RayStation since 2018 and has now ordered additional licenses as well as upgrades to the system.
We have seen a sharp increase in interest for RayCare. In addition to that fact that RayCare is seen as a next generation oncology information system, this was mainly driven by three factors. The first is the positive
feedback provided by reference customers, such as Swiss Medical Network in Switzerland and UZ Leuven in Belgium. Furthermore, we can see that RaySearch's strong offering in proton therapy – which has given us a market-leading position – means new, potential proton customers look upon RayCare as an attractive alternative. Lastly, we expect to see increased interest when it becomes possible to connect RayCare to Varian's TrueBeam later in the year. We believe most interest in acquiring RayCare will be shown by centers with treatment machines from several different manufacturers.
RAYCOMMAND IN CLINICAL USE
An important milestone was reached in April when RaySearch's latest product, RayCommand, was taken into clinical use for the first time, which occurred at MedAustron in Austria. MedAustron has used RayStation for some time to plan carbon ion therapy, which is the most advanced form of radiation therapy. RaySearch and MedAustron have had a unique and close cooperation for several years in the development of RayCommand and it is very gratifying to see how this has now resulted in a new and innovative product. Earlier this spring, MedAustron also took RayCare into clinical use and therefore became the first center in the world to use the three systems – RayStation, RayCare and RayCommand – together to treat patients. The RayCommand treatment delivery system serves as a link between the treatment machine, RayStation and RayCare and also coordinates and orchestrates the other systems at the center, such as imaging systems, beam delivery systems and the patient positioning systems.
Another key milestone after the end of the quarter was that Swiss Medical Network in Switzerland treated its first patient using Accuray's CyberKnife treatment delivery system together with RayStation and RayCare. In addition to these two extraordinary events, product development is progressing according to plan for all products and RayStation and RayCare are both in the final phase ahead of their half-year launches in June.
WELL POSITIONED FOR GROWTH
The cost-saving program initiated in autumn 2021 is continuing and we can see a clear reduction in costs for travel and events as well as a slight decrease in personnel costs as a result of the continued recruitment freeze. Given all of the positive signals from the market, I am optimistic about the future. Concurrently, I am retaining a realistic view of business, well aware of the fact that we have yet to fully leave the pandemic behind us. We will therefore continue along the route we have set, focusing on sales, product development and cost control. With this strategy, combined with improving market conditions, a quarter with strong figures and an order backlog that once again achieved a new peak (SEK 1,489 M), we have an solid foundation for a return to growth during the year.
Stockholm, May 18, 2022
Johan Löf CEO and founder
FINANCIAL INFORMATION
RaySearch operates in a market with uneven order flows where large individual orders can have a substantial impact on revenue recognition between the quarters and, because the company has limited (less than 10 percent) variable costs for license revenue, operating profit is affected by an amount that is nearly as high. For this reason, a longer perspective than a few quarters should be taken.
ORDER INTAKE AND ORDER BACKLOG
In the first quarter of 2022, order intake rose 87.8 percent year-on-year to SEK 272.5 M (145.1). License order intake increased 68.5 percent to SEK 131.4 M (78.0) while order intake for support increased 128.8 percent to SEK 111.2 M (48.6).
| Order intake (amounts in SEK M) | Q1-22 | Q4-21 | Q3-21 | Q2-21 | Q1-21 | Rolling 12 months |
Full-year 2021 |
|---|---|---|---|---|---|---|---|
| Licenses | 131.4 | 170.9 | 46.2 | 55.6 | 78.0 | 404.1 | 350.7 |
| Hardware | 24.1 | 35.7 | 7.9 | 9.3 | 12.1 | 77.0 | 65.0 |
| Support (incl. warranty support) | 111.2 | 130.7 | 69.1 | 116.6 | 48.6 | 427.6 | 365.0 |
| Training and other | 5.8 | 7.7 | 4.7 | 8.2 | 6.5 | 26.4 | 27.1 |
| Total order intake | 272.5 | 345.0 | 127.9 | 189.8 | 145.1 | 935.1 | 807.8 |
| Order backlog (amounts in SEK M) | Q1-22 | Q4-21 | Q3-21 | Q2-21 | Q1-21 | ||
| Licenses | 184.1 | 176.6 | 105.3 | 115.0 | 129.6 | ||
| Hardware | 74.2 | 66.2 | 38.4 | 36.9 | 48.5 | ||
| Support (incl. warranty support) | 1,159.9 | 1,053.3 | 1,009.2 | 1,001.7 | 974.2 | ||
| Training and other | 70.5 | 66.8 | 59.5 | 59.9 | 54.8 | ||
| Total order backlog at the end of the period | 1,488.7 | 1,362.9 | 1,212.4 | 1,213.4 | 1,207.1 |
At March 31, 2022, the total order backlog was SEK 1,488.7 M (1,207.1), which is expected to generate revenue of approximately SEK 422 M over the next 12 months. The remaining amount in the order backlog mainly pertains to support obligations, which are primarily expected to generate revenue over a subsequent four-year period.
REVENUE
In the first quarter of 2022, net sales rose 28.4 percent year-on-year to SEK 208.1 M (162.1). The change was attributable to higher license sales, which rose 35.2 percent to SEK 111.7 M (82.6). The increase in net sales at unchanged currencies was 15.9 percent (-14.2).
Support revenue rose 23.8 percent to SEK 76.6 M (61.9), accounting for 36.8 percent (38.2) of net sales during the first quarter. Hardware sales, which have a limited profit margin, rose 7.8 percent to SEK 16.6 M (15.4). Excluding hardware, sales rose 30.6 percent year-on-year.
| Revenue (amounts in SEK M) | Q1-22 | Q4-21 | Q3-21 | Q2-21 | Q1-21 | Rolling 12 months |
Full year 2021 |
|---|---|---|---|---|---|---|---|
| License revenue | 111.7 | 105.5 | 55.7 | 63.4 | 82.6 | 336.2 | 307.1 |
| Hardware revenue | 16.6 | 9.2 | 7.1 | 19.8 | 15.4 | 52.7 | 51.5 |
| Support revenue | 76.6 | 71.8 | 67.3 | 67.5 | 61.9 | 283.2 | 268.5 |
| Training and other revenue | 3.2 | 2.1 | 6.4 | 3.9 | 2.1 | 15.6 | 14.5 |
| Net sales | 208.1 | 188.6 | 136.4 | 154.6 | 162.1 | 687.7 | 641.7 |
| Change in sales, corresp. period, % | 28.4 | 17.6 | 14.5 | -5.6 | -22.4 | 13.7 | -1.6 |
| Change in organic sales, corresp. period, % | 15.9 | 22.0 | 11.9 | 4.5 | -14.2 | 13.2 | 1.6 |
In the first quarter of 2022, net sales had the following geographic distribution: North America, 39 percent (36); Asia, 29 percent (26); Europe and the rest of the world, 32 percent (38).
OPERATING PROFIT
In the first quarter of 2022, operating profit totaled SEK 29.6 M (12.3), representing an operating margin of 14.2 percent (7.6). The earnings improvement was largely attributable to higher license revenue.
In the first quarter, operating expenses increased 19.2 percent to SEK 178.6 M (149.8). The change was largely due to increased administrative costs.
In the first quarter, the net of exchange gains and losses amounted to SEK 4.9 M (10.0) since a large proportion of the Group's receivables are denominated in USD and EUR, which strengthened against the SEK in the first quarter compared with the end of the fourth quarter. Adjusted for these currency translation effects, operating profit would have totaled SEK 24.7 M (2.3) in the first quarter and operating expenses would have increased 14.8 percent (-11.1).
Currency effects
Consolidated sales and earnings are impacted by USD/EUR to SEK exchange rates, since most sales are invoiced in USD and EUR, while most costs are denominated in SEK.
At unchanged exchange rates, the change in sales was 15.9 percent in the first quarter of 2022, compared with the yearearlier period. In addition, the Group's exchange gains on balance sheet items amounted to SEK 4.4 M (10.0) in the first quarter. Currency effects therefore had a positive impact on net sales and operating profit in the first quarter 2022.
A sensitivity analysis of the Group's currency exposure shows that a 1-percentage point change in the USD exchange rate against the SEK would have impacted consolidated operating profit by approximately +/- SEK 2.6 M in the first quarter of 2022, while a corresponding change in the EUR exchange rate would have impacted consolidated operating profit by approximately +/- SEK 1.4 M.
The Group follows the financial policy established by the Board, whereby exchange-rate fluctuations are not hedged.
Capitalization of development costs
RaySearch is a research and development-oriented company that makes significant investments in the development of software solutions for improved cancer treatment. At March 31, 2022, some 199 employees (210) were engaged in research and development, corresponding to 50 percent (51) of the total number of employees.
INTERIM REPORT JANUARY 1-MARCH 31, 2022
| Capitalization of development costs | Q1-22 | Q4-21 | Q3-21 | Q2-21 | Q1-21 | Rolling 12 months |
Full-year 2021 |
|---|---|---|---|---|---|---|---|
| Research and development costs | 64.3 | 79.1 | 57.9 | 68.0 | 64.9 | 269.4 | 270.0 |
| Capitalization of development costs | -52.4 | -59.3 | -40.0 | -52.5 | -51.5 | -204.1 | -203.3 |
| Amortization of capitalized development costs | 45.0 | 44.1 | 43.2 | 40.1 | 39.2 | 172.5 | 166.7 |
| Research and development costs | 57.0 | 63.9 | 61.2 | 55.7 | 52.6 | 237.8 | 233.4 |
In 2022, RaySearch continued to invest in both existing products and future products. Overall, research and development costs decreased 1 percent to SEK 64.3 M (64.9) in the first quarter of 2022, corresponding to 31 percent (40) of the Group's net sales.
Development costs of SEK 52.4 M (51.5) were capitalized, up 1.7 percent, corresponding to 81 percent (79) of total research and development costs.
Amortization of capitalized development costs rose 14.7 percent to SEK 45.0 M (39.2), and the increase was attributable to an expansion of development activities, and that amortization periods had commenced for all products, including RayCommand and RayIntelligence.
Research and development costs (after adjustments for capitalization and amortization of development costs) rose 8.2 percent to SEK 57.0 M (52.6).
Amortization and depreciation
In the first quarter of 2022, total amortization and depreciation rose 19.8 percent to SEK 70.0 M (58.3), of which amortization of intangible fixed assets accounted for SEK 45.0 M (39.3), mainly related to capitalized development costs. Depreciation of tangible fixed assets amounted to SEK 25.0 M (19.1).
PROFIT AND EARNINGS PER SHARE
In the first quarter of 2022, profit after tax was SEK 19.3 M (7.1), corresponding to earnings per share of SEK 0.56 (0.21) before and after dilution.
Tax expense for the quarter was SEK -6.9 M (-4.3), corresponding to an effective tax rate of 26.2 percent (37.5).
CASH FLOW AND LIQUIDITY
In the first quarter of 2022, cash flow from operating activities was SEK 125.8 M (104.3) and the change was largely attributable to a decrease in working capital, which mainly comprises various types of receivables from customers, such as accounts receivable and current and long-term unbilled customer receivables where payment plans have been drawn up.
At the end of the period, the company's total customer receivables amounted to 46 percent (56) of net sales over the past 12 months.
Working capital amounted to 2 percent (5) of net sales over the past 12 months.
In the first quarter, cash flow from investing activities was SEK -60.6 M (-60.3). Investments in intangible fixed assets amounted to SEK -52.4 M (-51.5) and consisted of capitalized development costs for the company's products – RayStation, RayCare, RayCommand and RayIntelligence. Investments in tangible fixed assets amounted to SEK -8.2 M (-8.8), mainly related to investments in the head office in Stockholm.
Cash flow from financing activities was SEK -29.9 M (-11.2) for the first quarter of 2022. The change was largely due to a bank overdraft of SEK 21 M drawn in the first quarter.
Cash flow for the first quarter amounted to SEK 35.3 M (32.8). At March 31, 2022, consolidated cash and cash equivalents amounted to SEK 139.8 M (205.2).
FINANCIAL POSITION
At March 31, 2022, RaySearch's total assets amounted to SEK 1,722 M (1,334) and the equity/assets ratio was 38.9 percent (52.7). The change in total assets and the equity/assets ratio was largely attributable to an increase in right-of-use assets related to rented premises following the granting of access to the new head office premises.
Current receivables amounted to SEK 376.7 M (414.3). The receivables mainly comprise various types of customer receivables.
RaySearch's credit facility comprises a revolving loan facility of up to SEK 150 M that matures in March 2025 and an overdraft facility of SEK 50 M the matures in December 2022. Chattel mortgages amounted to SEK 100 M. At March 31, 2022, a short-term loan of SEK 0 M (50) was raised under the company's revolving loan facility and SEK 0 M (0) of the credit facility had been drawn.
At March 31, 2022, the Group's net debt amounted to SEK 397.0 M (-66.0). The change was largely due to an increase in lease liabilities following the granting of access to the new head office premises during the fourth quarter.
EMPLOYEES
At the end of the first quarter, the Group had 389 (413) employees, of whom 284 (310) were based in Sweden, and 105 (102) in foreign subsidiaries.
PARENT COMPANY
RaySearch Laboratories AB (publ) is the Parent Company of the RaySearch Group. Since the Parent Company's operations are consistent with the Group's operations in all material respects, the comments for the Group are also largely relevant for the Parent Company.
Differences in profitability between the Parent Company and the Group are attributable to the Parent Company accounting for a relatively high proportion of operating expenses, and to the capitalization of development costs being recognized in the Group but not in the Parent Company. The Parent Company was also not affected by the changes pertaining to lease recognition under IFRS 16, and instead continues to recognize lease payments as operating lease payments. This reduces operating profit compared with if IFRS 16 had been applied.
The Parent Company's current receivables mainly comprise receivables from Group companies and external customers.
SIGNIFICANT EVENTS DURING THE FIRST QUARTER
Agreement signed with Proton International Arkansas
In January, RaySearch signed an agreement with Proton International Arkansas to provide RayStation at the UAMS Radiation Oncology Center. The center will open in 2023 and be the first proton center in the state of Arkansas.The center at UAMS brings RaySearch's presence in proton therapy to thirty centers in the United States, a large majority of operating facilities.
Agreement with Charles-Le Moyne in Canada
In February, Montérégie Integrated Cancer Center (CICM), which is part of the Charles-Le Moyne hospital in Longueuil in Quebec in Canada, placed an order for additional RayStation licenses as well as upgrades to the system which includes advanced treatment planning functionality.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
Agreement with Hong Kong Sanatorium & Hospital
In April, Hong Kong Sanatorium & Hospital placed an order for RayStation as treatment planning system for its proton therapy center. The hospital thereby became RaySearch's first customer in Hong Kong within the proton therapy segment.
Agreement with Seoul National University Hospital
In April, Seoul National University Hospital (SNUH) placed an order for RayStation. SNUH is the second carbon ion center in Korea to select RaySearch, the first customer was Yonsei Cancer Center in Seoul.
Agreement with Mevion China
In April, Mevion China placed an order for RayStation, which it sold together with Mevion's proton therapy system to Tongji Hospital in Wuhan in China. RaySearch and Mevion have been collaborating since 2014. Treatment planning for particle treatments (protons/carbon ions/BNCT) is an important focus area for RaySearch and today RayStation has a global market share of more than 60 percent, a position that is further strengthened by the new order.
Agreement with GE Healthcare
In May, RaySearch entered into an agreement with GE Healthcare to develop a new radiation therapy simulation and treatment planning workflow solution designed to make use of the latest advancements in treatment planning technology. The companies aim to combine RaySearch's advanced treatment planning system RayStation with GE Healthcare's leading multi-modality (CT/MR/molecular imaging) simulator systems to make cancer treatment faster and more precise.
RayCare taken into clinical use with CyberKnife at Swiss Medical Network in Switzerland
In May, RayCare was taken into clinical use with Accuray's CyberKnife treatment delivery system at La Clinique Générale-Beaulieu, a part of Swiss Medical Network in Switzerland. The center became first in the world to treat a patient using RayCare and CyberKnife.
Management change
Torbjörn Wingårdh stepped down as CFO of RaySearch on April 4, 2022.
EFFECTS OF THE COVID-19 PANDEMIC
Even though the pandemic is over in most countries, the effects of it remain a challenge for many operations. RaySearch is monitoring the situation closely and is prepared to take new action and align the company's operations if needed.
Effects on RaySearch's operations in the first quarter of 2022
Sales. The negative effect of the pandemic on RaySearch's sales appears to be weakening as the pandemic subsides. In Asia, market conditions normalized and conditions improved in Europe and the US during the quarter.
Delivery capacity. As a software company, RaySearch is well equipped for remote collaboration and both our R&D and delivery capacity have remained relatively unscathed by the COVID-19 pandemic to date.
In the first quarter, COVID-19 did not have any major impact on the company's assessment items.
Expected future effects
It is still difficult to say how the ongoing pandemic will affect the coming quarters with any great certainty. The situation has normalized in most countries, though a few countries have registered rising case numbers.
The company believes the underlying need and demand for effective software solutions for cancer care is in the process of returning to pre-pandemic levels. Since sales activities have been restricted for some time, however, it may take time before the full sales effect is regained. We see no major challenges in terms of R&D or the company's delivery capacity. The company will continue to focus on protecting the company's cash flow and liquidity.
Increased focus on efficiencies and digitization. One effect of the COVID-19 pandemic could be a further acceleration of the ongoing digital transformation. The pandemic has drastically highlighted the major potential and benefits of digital technology, which could be positive for RaySearch's operations in the long term because the company's software solutions enable cancer clinics to improve their efficiency.
THE COMPANY'S SHARE
At March 31, 2022, the total number of registered shares in RaySearch was 34,282,773, of which 8,454,975 were Class A and 25,827,798 Class B shares.The quotient value is SEK 0.50 and the company's share capital amounts to SEK 17,141,386.50. Holders of Class A shares are entitled to 10 votes per share, and holders of Class B shares are entitled to one vote per share, at General Meetings. At March 31, 2022, the total number of votes in RaySearch was 110,377,548.
SHARE OWNERSHIP
At March 31, 2022, the number of shareholders in RaySearch was 6,767, according to Euroclear, and the largest shareholders were as follows:
| Class A | Class B | Share | |||
|---|---|---|---|---|---|
| Name | shares | shares | Total shares | capital, % | Votes, % |
| Johan Löf | 6,243,084 | 318,393 | 6,561,477 | 19.1 | 56.8 |
| Invesco fonder | 0 | 4,254,309 | 4,254,309 | 12.4 | 3.9 |
| La Financière de l'Echiquier | 0 | 2,652,240 | 2,652,240 | 7.7 | 2.4 |
| First AP Fund | 0 | 1,982,448 | 1,982,448 | 5.8 | 1.8 |
| Swedbank Robur Funds | 0 | 1,800,000 | 1,800,000 | 5.3 | 1.6 |
| Anders Brahme | 1,150,161 | 200,000 | 1,350,161 | 3.9 | 10.6 |
| Second AP Fund | 0 | 1,220,942 | 1,220,942 | 3.6 | 1.1 |
| Carl Filip Bergendal | 1,061,577 | 139,920 | 1,201,497 | 3.5 | 9.7 |
| C WorldWide Asset Management | 0 | 935,249 | 935,249 | 2.7 | 0.8 |
| Avanza Pension | 0 | 564,685 | 564,685 | 1.6 | 0.5 |
| Total, 10 largest shareholders | 8,454,822 | 14,068,186 | 22,523,008 | 65.7 | 89.3 |
| Others | 153 | 11,759,612 | 11,759,765 | 34.3 | 10.7 |
| Total | 8,454,975 | 25,827,798 | 34,282,773 | 100.0 | 100.0 |
Source: Euroclear
OTHER INFORMATION
2022 ANNUAL GENERAL MEETING
The Annual General Meeting (AGM) of RaySearch Laboratories AB (publ) will take place on Wednesday, May 25, 2022 and be held by postal vote only. This means the Meeting will take place without the physical presence of shareholders, agents or outsiders. The exercise of voting rights by shareholders at the Meeting can therefore only take place by shareholders submitting a postal vote using the procedure stipulated in the Notice of the Annual General Meeting, which was published on April 22, 2022 and is available on RaySearch's website.
Proposed dividend
Since the company is in the midst of an expansive and capital-intensive phase, the Board of RaySearch proposes that no dividend be paid for the 2022 fiscal year.
RISKS AND UNCERTAINTIES
As a global Group with operations in different parts of the world, RaySearch is exposed to various risks and uncertainties, such as market risk, operational and legal risk, as well as financial risk pertaining to exchange-rate fluctuations, interest rates, liquidity and financing opportunities. RaySearch's risk management aims to identify, measure and reduce risks related to the Group's transactions and operations. For more information about risks and risk management, refer to pages 39-41 of RaySearch's 2021 Annual Report. There have been no significant changes with any impact on the risks reported. This also applies to the risks and uncertainties arising from the COVID-19 pandemic that could affect RaySearch's sales, earnings and financial position.
SEASONAL VARIATIONS
RaySearch's customers are healthcare providers and the company's operations are somewhat characterized by seasonal variations that are typical for the industry, whereby the fourth quarter is normally the strongest – mainly because many customers have budgets that follow the calendar year.
ENVIRONMENT AND SUSTAINABILITY
Sustainability is a key aspect of RaySearch's strategy and operations, and the company is working actively to become a sustainable enterprise. The primary aim of RaySearch's operations is to help cancer clinics improve and save the lives of cancer patients. Through innovative software solutions, the company is continuously striving to improve and streamline workflows in clinical environments and to improve treatment outcomes for cancer patients. The customer value created presents business opportunities for RaySearch, but also major social benefit and economic gains.
The negative environmental impact of the company's products is limited. The company's environmental impact is mainly related to the purchase of goods and services, energy use and transportation. RaySearch aims to contribute to sustainable development and therefore works actively to improve the company's environmental performance wherever this is economically viable. More information about the company's environmental and sustainability initiatives is available in the company's Sustainability Report on pages 22-28 of RaySearch's 2021 Annual Report.
REVIEW
This interim report has not been reviewed by the company's auditors.
The Board of Directors and CEO give their assurance that this interim report gives a true and fair view of the Group's and the Parent Company's operations, position and earnings, and describes the significant risks and uncertainties facing the Parent Company and the companies included in the Group.
Stockholm, May 18, 2022 The Board of Directors of RaySearch Laboratories AB (publ)
Lars Wollung Chairman of the Board Johan Löf CEO and Board member Carl Filip Bergendal Board member
Britta Wallgren Board member Hans Wigzell Board member Johanna Öberg Board member
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, CEO Tel: +46 (0)8 510 530 00 [email protected]
Björn Hårdemark Interim CFO Tel: +46 (0)70 95 642 17 [email protected]
The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on May 18, 2022 at 7:45 a.m. CEST.
WEBCAST
CEO Johan Löf and Interim CFO Björn Hårdemark will present RaySearch's interim report for January-March 2022 at a webcast to be held in English on Wednesday, May 18, 2022 at 10:00-10:30 a.m. CEST.
Link to webcast: https://raysearchlabs.creo.se/220518
You can also join the webcast by phone: Sweden +46 8 505 583 51 UK: +44 333 300 92 67 US: +1 646 722 49 56
FINANCIAL CALENDAR
Annual General Meeting 2022 Interim report for the second quarter, 2022 Interim report for the third quarter, 2022
May 25, 2022 August 25, 2022 November 17, 2022
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME IN SUMMARY
| AMOUNTS IN SEK 000s | JAN-MAR | APR 2021- | FULL-YEAR | |
|---|---|---|---|---|
| Note | 2022 | 2021 | MAR 2022 | 2021 |
| Net sales 2.3 |
208,149 | 162,102 | 687,720 | 641,673 |
| Cost of goods sold1 | -14,652 | -15,220 | -49,829 | -50,397 |
| Gross profit | 193,497 | 146,882 | 637,891 | 591,276 |
| Other operating income | 14,452 | 17,150 | 30,081 | 32,779 |
| Selling expenses | -70,462 | -65,260 | -305,394 | -300,192 |
| Administrative expenses | -41,361 | -26,702 | -136,695 | -122,036 |
| Research and development costs | -56,972 | -52,636 | -237,779 | -233,443 |
| Other operating expenses | -9,590 | -7,173 | -24,142 | -21,725 |
| Operating profit/loss | 29,564 | 12,261 | -36,038 | -53,341 |
| Loss from financial items | -3,403 | -879 | -7,856 | -5,332 |
| Profit/loss before tax | 26,161 | 11,382 | -43,894 | -58,673 |
| Tax | -6,863 | -4,272 | 8,767 | 11,358 |
| Profit/loss for the period2 | 19,298 | 7,110 | -35,127 | -47,315 |
| Other comprehensive income | ||||
| Items to be reclassified to profit or loss | ||||
| Translation difference of foreign operations for the period | 638 | 1,130 | 1,750 | 2,242 |
| Comprehensive income for the period2 | 19,935 | 8,240 | -33,377 | -45,073 |
| Earnings/loss per share before and after dilution (SEK) | 0.56 | 0.21 | -1.02 | -1.38 |
1 Comprises costs for hardware and license costs paid, but not amortization of capitalized development costs, which is included in research and development costs.
2 Fully (100 percent) attributable to Parent Company shareholders.
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY IN SUMMARY
| AMOUNTS IN SEK 000s | JAN-MAR | FULL-YEAR | |
|---|---|---|---|
| 2022 | 2021 | 2021 | |
| Opening balance according to adopted Annual Report | 649,278 | 694,351 | 694,351 |
| Profit/loss for the period | 19,298 | 7,110 | -47,315 |
| Translation difference for the period | 637 | 1,130 | 2,242 |
| Closing balance | 669,213 | 702,591 | 649,278 |
CONSOLIDATED STATEMENT OF FINANCIAL POSITION IN SUMMARY
| AMOUNTS IN SEK 000s Note |
Mar 31, 2022 | Mar 31, 2021 | Dec 31, 2021 |
|---|---|---|---|
| ASSETS | |||
| Intangible fixed assets | 530,427 | 499,031 | 523,109 |
| Tangible fixed assets | 650,769 | 183,327 | 666,539 |
| Deferred tax assets | 18,511 | 5,381 | 22,817 |
| Other long-term receivables | 6,291 | 26,223 | 10,204 |
| Total fixed assets | 1,205,998 | 713,962 | 1,222,669 |
| Inventories | 38,452 | 22,189 | 29,991 |
| Current receivables | 338,224 | 392,145 | 383,843 |
| Cash and cash equivalents | 139,816 | 205,215 | 102,535 |
| Total current assets | 516,492 | 619,549 | 516,369 |
| TOTAL ASSETS | 1,722,490 | 1,333,511 | 1,739,038 |
| EQUITY AND LIABILITIES | |||
| Equity | 669,213 | 702,591 | 649,278 |
| Deferred tax liabilities | 109,294 | 110,185 | 107,784 |
| Long-term interest-bearing liabilities | 486,361 | 54,435 | 491,896 |
| Total long-term liabilities | 595,655 | 164,620 | 599,680 |
| Accounts payable | 29,852 | 21,975 | 48,774 |
| Current interest-bearing liabilities | 50,500 | 84,828 | 70,381 |
| Other current liabilities | 377,270 | 359,497 | 370,925 |
| Total current liabilities | 457,622 | 466,300 | 490,080 |
| TOTAL EQUITY AND LIABILITIES | 1,722,490 | 1,333,511 | 1,739,038 |
CONSOLIDATED STATEMENT OF CASH FLOW IN SUMMARY
| AMOUNTS IN SEK 000s | JAN-MAR | APRIL 2021 - | FULL-YEAR | |
|---|---|---|---|---|
| Note | 2022 | 2021 | MAR 2022 | 2021 |
| Profit/loss before tax | 26,161 | 11,382 | -43,894 | -58,673 |
| Adjusted for non-cash items1) | 70,091 | 42,488 | 254,240 | 226,637 |
| Taxes paid | -3,456 | -6,266 | 20,458 | 17,648 |
| Cash flow from operating activities before changes in working capital | 92,796 | 47,604 | 230,804 | 185,612 |
| Cash flow from changes in operating receivables | 45,553 | 30,667 | 31,939 | 17,053 |
| Cash flow from changes in operating liabilities | -12,562 | 26,061 | -3,126 | 35,497 |
| Cash flow from operating activities | 125,787 | 104,332 | 259,617 | 238,162 |
| Cash flow from investing activities | -60,551 | -60,275 | -237,907 | -237,631 |
| Cash flow from financing activities | -29,916 | -11,217 | -90,933 | -72,234 |
| Cash flow for the period | 35,320 | 32,840 | -69,223 | -71,703 |
| Cash and cash equivalents at the beginning of the period | 102,535 | 168,746 | 205,215 | 168,746 |
| Exchange-rate difference in cash and cash equivalents | 1,961 | 3,629 | 3,824 | 5,492 |
| Cash and cash equivalents at the end of the period | 139,816 | 205,215 | 139,816 | 102,535 |
1 These amounts mainly include amortization of capitalized development costs, right-of-use assets and unrealized currency effects.
PARENT COMPANY INCOME STATEMENT IN SUMMARY
| AMOUNTS IN SEK 000s | JAN-MAR | FULL-YEAR | |
|---|---|---|---|
| Note | 2022 | 2021 | 2021 |
| Net sales | 161,864 | 122,484 | 477,055 |
| Cost of goods sold1) | -2,966 | -7,643 | -26,477 |
| Gross profit | 158,898 | 114,841 | 450,578 |
| Other operating income | 14,354 | 17,015 | 32,227 |
| Selling expenses | -42,472 | -37,434 | -177,313 |
| Administrative expenses | -41,528 | -26,436 | -122,793 |
| Research and development costs | -64,926 | -65,209 | -270,868 |
| Other operating expenses | -9,755 | -7,154 | -20,704 |
| Operating profit/loss | 14,571 | -4,377 | -108,873 |
| Loss from financial items | -1,164 | -200 | -1,618 |
| Profit/loss after financial items | 13,407 | -4,577 | -110,491 |
| Appropriations | 0 | 0 | 32,615 |
| Profit/loss before tax | 13,407 | -4,577 | -77,876 |
| Tax on profit/loss for the period | -2,738 | 489 | 14,367 |
| Profit/loss for the period | 10,669 | -4,088 | -63,509 |
1 Comprises costs for hardware and royalties but not amortization of capitalized development costs, which is included in research and development costs.
PARENT COMPANY STATEMENT OF COMPREHENSIVE INCOME
| AMOUNTS IN SEK 000s | JAN-MAR | FULL-YEAR | |
|---|---|---|---|
| 2022 | 2021 | 2021 | |
| Profit/loss for the period | 10,669 | -4,088 | -63,509 |
| Other comprehensive income | - | - | - |
| Comprehensive income for the period | 10,669 | -4,088 | -63,509 |
PARENT COMPANY BALANCE SHEET IN SUMMARY
| AMOUNTS IN SEK 000s Note |
Mar 31, 2022 | Mar 31, 2021 | Dec 31, 2021 |
|---|---|---|---|
| ASSETS | |||
| Intangible fixed assets | 518 | 750 | 575 |
| Tangible fixed assets | 66,379 | 47,200 | 69,225 |
| Shares and participations | 3,958 | 3,958 | 3,958 |
| Deferred tax assets | 18,250 | 6,866 | 20,987 |
| Long-term receivables from Group companies | 0 | 27,157 | 0 |
| Other long-term receivables | 12,247 | 7,516 | 16,344 |
| Total fixed assets | 101,352 | 93,447 | 111,089 |
| Inventories | 9,798 | 22 | 6436 |
| Current receivables | 297,081 | 327,655 | 360,363 |
| Cash and bank balances | 59,504 | 122,500 | 11,165 |
| Total current assets | 366,383 | 450,177 | 377,964 |
| TOTAL ASSETS | 467,735 | 543,624 | 489,053 |
| EQUITY AND LIABILITIES | |||
| Equity | |||
| Restricted equity | |||
| Share capital | 17,141 | 17,141 | 17,141 |
| Statutory reserve | 43,630 | 43,630 | 43,630 |
| Total restricted equity | 60,771 | 60,771 | 60,771 |
| Unrestricted equity | |||
| Retained earnings | 139,190 | 202,699 | 202,699 |
| Profit/loss for the year | 10,669 | -4,088 | -63,509 |
| Total non-restricted equity | 149,859 | 198,611 | 139,190 |
| Total equity | 210,630 | 259,382 | 199,961 |
| Untaxed reserves | 0 | 32,615 | 0 |
| Long-term liabilities | 11,976 | 879 | 6,447 |
| Accounts payable1) | 25,192 | 11,656 | 40,169 |
| Current interest-bearing liabilities | 0 | 49,674 | 21,268 |
| Other current liabilities1) | 219,937 | 189,418 | 221,208 |
| Total current liabilities | 245,129 | 250,748 | 282,645 |
| TOTAL EQUITY AND LIABILITIES | 467,735 | 543,624 | 489,053 |
1 The reclassification of comparative figures is based on other current liabilities to accounts payable pertaining to intra-Group accounts payable of SEK 11.1 M.
NOTES, GROUP
NOTE 1 ACCOUNTING POLICIES
The RaySearch Group applies International Financial Reporting Standards (IFRS) as adopted by the EU. The accounting policies applied are consistent with those described in the 2021 Annual Report for RaySearch Laboratories AB (publ), which is available at www.raysearchlabs.com This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act.
RaySearch Laboratories AB (publ) is the Parent Company of the RaySearch Group. The Parent Company applies the Swedish Annual Accounts Act and RFR 2 Accounting for Legal Entities. The Parent Company's operations are consistent with the Group's operations in all material respects.
Differences in profitability between the Parent Company and the Group are attributable to the Parent Company accounting for a relatively high proportion of operating expenses, and to the capitalization of development costs being recognized in the Group but not in the Parent Company. The Parent Company was also not affected by IFRS 16, and will continue to recognize lease payments on a straight-line basis over the lease term. This reduces operating profit compared with if IFRS 16 had been applied.
The Parent Company's current receivables mainly comprise receivables from Group companies and external customers.
NOTE 2 REVENUE FROM CONTRACTS WITH CUSTOMERS
RaySearch conducts sales of goods and services in various regions. Revenue from sales of licenses and hardware is recognized in profit or loss at a point in time, while revenue from sales of training and support is recognized over time.
| AMOUNTS IN SEK 000s | JAN-MAR | ||||
|---|---|---|---|---|---|
| 2022 | 2021 | Change | APR 2021- MAR 2022 |
Full-year 2021 |
|
| Revenue by type | |||||
| Licenses | 111,711 | 82,605 | 35.2% | 336,244 | 307,138 |
| Support | 76,644 | 61,937 | 23.7% | 283,233 | 268,526 |
| Hardware | 16,597 | 15,428 | 7.6% | 52,665 | 51,496 |
| Training and other | 3,197 | 2,132 | 50.0% | 15,578 | 14,513 |
| Total revenue from contracts with customers | 208,149 | 162,102 | 28.4% | 687,720 | 641,673 |
| Revenue by geographic market | |||||
| North America | 79,993 | 58,688 | 36.3% | 245,646 | 224,341 |
| APAC | 61,037 | 41,718 | 46.3% | 192,866 | 173,547 |
| Europe and rest of the world | 67,119 | 61,696 | 8.8% | 249,208 | 243,785 |
| Total revenue from contracts with customers | 208,149 | 162,102 | 28.4% | 687,720 | 641,673 |
| Revenue by date for revenue recognition | |||||
| Goods/services transferred at a point in time | 128,308 | 98,033 | 30.9% | 388,909 | 358,634 |
| Services transferred over time | 79,841 | 64,069 | 24.6% | 298,811 | 283,039 |
| Total revenue from contracts with customers | 208,149 | 162,102 | 28.4% | 687,720 | 641,673 |
NOTE 3 ESTIMATES
Preparation of the interim report requires that company management make estimates that affect the carrying amounts. The actual outcome could deviate from these estimates. The critical sources of uncertainty in the estimates are the same as those in the most recent Annual Report.
NOTE 4 FINANCIAL INSTRUMENTS
RaySearch's financial assets and liabilities comprise billed and unbilled receivables, cash and cash equivalents, accrued expenses, accounts payable, bank loans and lease liabilities. Long-term receivables and lease liabilities are discounted, while other financial assets and liabilities have short maturities. Accordingly, the fair values of all financial instruments are deemed to correspond approximately to their carrying amounts.
The provision for expected credit losses is a weighted assessment of payment history, reports from external credit rating agencies and other customer-specific information. At the end of March 2022, the credit loss provision amounted to SEK 40.0 M (26.7), corresponding to 12 percent (8) of total customer receivables. The increased credit loss provision despite lower total receivables was mainly related to a customer in the US. The Group's credit losses have historically been limited and amounted to about 0.7 percent of the company's average customer receivables over the past five years.
NOTE 5 RELATED-PARTY TRANSACTIONS
There were no transactions between RaySearch and related parties with any material impact on the company's position and earnings during the period.
NOTE 6 PLEDGED ASSETS IN THE GROUP AND PARENT COMPANY
| AMOUNTS IN SEK 000s | Mar 31, 2022 | Mar 31, 2021 | Dec 31, 2021 |
|---|---|---|---|
| Chattel mortgages | 100,000 | 100,000 | 100,000 |
| Guarantees | 31,314 | 14,815 | 31,046 |
The year-on-year increase was largely attributable to bank guarantees issued for the new office premises.
GROUP QUARTERLY OVERVIEW
| 2022 | 2021 | 2020 | ||||||
|---|---|---|---|---|---|---|---|---|
| AMOUNTS IN SEK 000s | Q1 | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 | Q2 |
| Order intake | ||||||||
| Total order intake | 272,442 | 345,028 | 127,853 | 189,750 | 145,131 | 239,125 | 138,480 | 177,133 |
| Income statement | ||||||||
| Net sales | 208,149 | 188,573 | 136,419 | 154,579 | 162,102 | 159,835 | 119,130 | 163,758 |
| Change in sales, % | 28.4 | 18.0 | 14.5 | -5.6 | -22.4 | -31.8 | -17.5 | -13.7 |
| Operating profit/loss | 29,564 | -16,578 | -26,561 | -22,463 | 12,261 | -14,592 | -29,477 | -10,954 |
| Operating margin, % | 14.2 | -8.8 | -19.5 | -14.5 | 7.6 | -9.1 | -24.7 | -6.7 |
| Profit/loss for the period | 19,298 | -15,968 | -21,990 | -16,467 | 7,110 | -14,164 | -26,182 | -9,196 |
| Net margin, % | 9.3 | -8.5 | -16.1 | -10.7 | 4.4 | -8.9 | -22.0 | -5.6 |
| Cash flow | ||||||||
| Operating activities | 125,787 | 28,397 | 47,356 | 58,077 | 104,332 | 51,505 | 78,486 | 135,443 |
| Investing activities | -60,551 | -60,944 | -45,569 | -70,843 | -60,275 | -64,094 | -45,372 | -55,913 |
| Financing activities | -29,916 | 12,482 | -11,875 | -61,624 | -11,217 | -8,909 | -11,394 | -13,618 |
| Cash flow for the period | 35,320 | -20,065 | -10,088 | -74,390 | 32,840 | -21,498 | 21,720 | 65,912 |
| Capital structure | ||||||||
| Equity/assets ratio, % | 38.9 | 37.3 | 56.7 | 57.8 | 52.7 | 54.0 | 57.0 | 56.2 |
| Net debt | 397,045 | 459,742 | -52,983 | -50,385 | -65,952 | -22,439 | -31,476 | 206 |
| Debt/equity ratio | 0.6 | 0.7 | -0.1 | -0.1 | -0.1 | 0.0 | 0.0 | 0.0 |
| Net debt/EBITDA | 1.8 | 2.3 | -0.3 | -0.3 | -0.4 | -0.1 | -0.1 | 0.0 |
| Per share data, SEK | ||||||||
| Earnings/loss per share before dilution | 0.56 | -0.47 | -0.64 | -0.48 | 0.21 | -0.41 | -0.76 | -0.27 |
| Earnings/loss per share after dilution | 0.56 | -0.47 | -0.64 | -0.48 | 0.21 | -0.41 | -0.76 | -0.27 |
| Equity per share | 19.52 | 18.94 | 19.38 | 20.00 | 20.49 | 20.25 | 20.71 | 21.48 |
| Share price at the end of the period | 51.70 | 56.50 | 61.50 | 87.40 | 89.50 | 82.70 | 87.50 | 86.50 |
| Other | ||||||||
| No. of shares before/after dilution, 000s | 34,282.8 | 34,282.8 | 34,282.8 | 34,282.8 | 34,282.8 | 34,282.8 | 34,282.8 | 34,282.8 |
| Average no. of employees | 399 | 419 | 418 | 414 | 412 | 404 | 399 | 391 |
GROUP, ROLLING 12 MONTHS
| AMOUNTS IN SEK 000s | Apr 2021- | Jan 2021- | Oct 2020- | Jul 2020- | Apr 2020- | Jan 2020- | Oct 2019- | Jul 2019- |
|---|---|---|---|---|---|---|---|---|
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | |
| Order intake | ||||||||
| Total order intake | 935,073 | 807,762 | 701,859 | 712,486 | 699,868 | 854,755 | 892,846 | 951,160 |
| Income statement | ||||||||
| Net sales | 687,720 | 641,673 | 612,935 | 595,646 | 604,825 | 651,612 | 726,276 | 751,495 |
| Operating profit/loss | -36,038 | -53,341 | -51,355 | -54,271 | -42,762 | -3,466 | 33,594 | 56,726 |
| Operating margin, % | -5.2 | -8.3 | -8.4 | -9.1 | -7.1 | -0.5 | 4.6 | 7.5 |
| Cash flow | ||||||||
| Cash flow | -69,223 | -72,380 | -73,136 | -41,328 | 98,972 | 61,890 | 91,165 | 55,970 |
| Cash flow adjusted for repayment of bank loans |
-47,955 | -22,380 | -23,136 | 8,672 | 98,972 | 61,890 | 91,165 | 55,970 |
DEFINITIONS OF KEY RATIOS
The interim report refers to a number of non-IFRS financial measures that are used to provide investors and company management with additional information to assess the company's operations. The various non-IFRS measures used to complement the IFRS financial statements are described below.
| Non-IFRS measures | Definition | Reason for using the measure |
|---|---|---|
| Order intake | The value (transaction price) of all orders received and changes to | Order intake is an indicator of future revenue and thus a key figure |
| existing orders during the current period | for the management of RaySearch's operations | |
| Order backlog | The value of orders at the end of the period that the company has | The order backlog shows the value of orders already booked by |
| yet to deliver and recognize as revenue, meaning remaining | RaySearch that will be converted to revenue in the future. | |
| performance obligations. | ||
| Net sales/Order intake | Recognized net sales in relation to total order intake during the | The measurement is used to monitor the recognized revenue in |
| corresponding period | relation to sales, which is part of the reason for the change in order | |
| backlog. | ||
| Change in sales | The change in net sales compared with the year-earlier period | The measure is used to track the performance of the company's |
| expressed as a percentage | operations between periods | |
| Change in sales at | Change in sales at unchanged exchange rates, i.e. excluding | This measure is used to monitor underlying change in sales driven |
| unchanged currencies | currency effects | by alterations in volume, pricing and mix for comparable units |
| between different periods | ||
| Gross profit | Net sales minus cost of goods sold | Gross profit is used to measure the margin before sales, research, |
| development and administrative expenses | ||
| Operating profit/loss | Calculated as profit for the period before financial items and tax | Operating profit/loss provides an overall picture of the total |
| generation of earnings in operating activities | ||
| Operating profit adjusted for | Calculated as operating profit less other operating | Operating profit provides an overall picture of the total generation of |
| currency translation effects | income/expenses | earnings in operating activities excluding currency translation |
| effects for balance sheet items | ||
| Operating margin | Operating profit expressed as a percentage of net sales | Together with sales growth, the operating margin is a key element |
| for monitoring value creation | ||
| Net margin | Profit for the period as a percentage of net sales for the period | The net margin shows the percentage of net sales remaining after |
| the company's expenses have been deducted | ||
| Cash flow adjusted for | Cash flow for the period less cash flow from changes to bank loans | The measurement shows the underlying cash flow before financing |
| changes in bank loans | activities, but including amortization of lease liabilities. | |
| Equity per share | Equity divided by number of shares at the end of the period | The measurement shows the return generated on the owners' |
| invested capital per share | ||
| Rolling 12 months' sales, | Sales, operating profit or other results measured over the past 12- | This measure is used to more clearly illustrate the trends for sales, |
| operating profit or other results |
month period | operating profit and other results, which is relevant because RaySearch's revenue is subject to monthly variations |
| Working capital | Working capital comprises inventories, operating receivables and | This measure shows how much working capital is tied up in |
| operating liabilities, and is obtained from the statement of financial | operations and can be shown in relation to net sales to | |
| position. Operating receivables comprise accounts receivable, | demonstrate the efficiency with which working capital has been | |
| other current/long-term receivables and non-interest bearing | used | |
| prepaid expenses and accrued income. Operating liabilities include | ||
| other non-interest bearing long-term liabilities, advance payments | ||
| from customers, accounts payable, other current liabilities and | ||
| non-interest bearing accrued expenses and deferred income. | ||
| Return on equity | Calculated as profit/loss for the period as a percentage of average | Shows the return generated on the owners' invested capital from a |
| equity. Average equity is calculated as the sum of equity at the end | shareholder perspective | |
| of the period plus equity at the end of the year-earlier period, | ||
| divided by two | ||
| Equity/assets ratio | Equity expressed as a percentage of total assets at the end of the | This is a standard measure to show financial risk, and is expressed |
| period | as the percentage of the total restricted equity financed by the | |
| owners | ||
| Net debt | Interest-bearing liabilities less cash and cash equivalents | This measure shows the Group's total indebtedness |
| and interest-bearing current and long-term receivables | ||
| Debt/equity ratio | Net debt in relation to equity | The measure shows financial risk and is used by management |
| to monitor the Group's indebtedness | ||
| EBITDA | Operating profit before financial items, tax, | The measurement is a way to evaluate the result without taking into |
| depreciation/amortization and impairment | consideration financial decisions or taxes | |
| Net debt/EBITDA | Net debt at the end of the period in relation to operating profit | A relevant measure from a credit perspective that shows the |
| before depreciation and amortization over the past 12-month | company's ability to handle its debt | |
| period |
CALCULATION OF FINANCIAL MEASURES NOT INCLUDED IN THE IFRS FRAMEWORK
| AMOUNTS IN SEK 000s | Mar 31, 2022 Mar 31, 2021 | Dec 31, 2021 |
|
|---|---|---|---|
| Working capital | |||
| Accounts receivable (current billed customer receivables) | 187,159 | 160,379 | 170,591 |
| Current unbilled customer receivables | 120,850 | 153,955 | 146,771 |
| Long-term unbilled customer receivables | 6,291 | 26,223 | 10,204 |
| Inventories | 38,452 | 22,189 | 29,991 |
| Other current receivables (excl. tax) | 67,322 | 47,762 | 63,702 |
| Accounts payable | -29,852 | -21,975 | -48,774 |
| Other current liabilities (excl. tax) | -375,819 | -356,215 | -367,212 |
| Working capital | 14,403 | 32,318 | 5,273 |
| AMOUNTS IN SEK 000s | Mar 31, 2022 Mar 31, 2021 | Dec 31, 2021 |
|
| Net debt | |||
| Current interest-bearing liabilities | 50,500 | 84,828 | 70,381 |
| Long-term interest-bearing liabilities | 486,361 | 54,435 | 491,017 |
| Cash and cash equivalents | -139,816 | -205,215 | -102,535 |
| Net debt | 397,045 | -65,952 | 458,863 |
| AMOUNTS IN SEK 000s | APR 2021- MAR 2022 |
APR 2020- MAR 2021 |
Full-year 2021 |
| EBITDA | |||
| Operating profit/loss | -36,038 | -42,762 | -53,341 |
| Amortization and depreciation | 261,665 | 222,165 | 250,184 |
| EBITDA | 225,627 | 179,403 | 196,843 |
| CHANGE IN SALES AT UNCHANGED CURRENCIES | APR 2021- MAR 2022 |
APR 2020- MAR 2021 |
Full-year 2021 |
| Net sales for the year | 706,117 | 604,825 | 641,673 |
| Currency adjustment | -2,859 | 29,482 | 20,868 |
| Adjusted Net sales | 684,861 | 634,307 | 662,541 |
| Net sales, preceding year | 604,825 | 777,395 | 651,612 |
| Organic growth | 13.2% | -18.4% | 1.7% |
HEAD OFFICE
RaySearch Laboratories AB (publ) Box 45169 SE-104 30 Stockholm, Sweden
STREET ADDRESS
Eugeniavägen 18 C SE-113 68 Stockholm, Sweden Tel: +46 (0)8 510 530 00 raysearchlabs.com Corp. Reg. No. 556322-6157
ABOUT RAYSEARCH
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to cancer centers all over the world and distributes the products through licensing agreements with leading medical technology companies.
In December 2020, the RayCommand treatment control system and RayIntelligence oncology analytics system were also launched. RaySearch's software is currently used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information about RaySearch is available at raysearchlabs.com.
VISION AND MISSION
The company's vision is a world where cancer is conquered and RaySearch's mission is to provide innovative software to continuously improve cancer treatment.
STRATEGY
A radiation therapy center essentially needs two software platforms for its operations: a treatment planning system, and an information system. With RayStation and RayCare, RaySearch will strengthen its position and continue to grow with high profitability. The company's strategy is based on a strong focus on innovative software development with leading functionality, support for efficient workflows – including via digitization and automation with machine learning – broad support for a wide range of treatment modes and radiation therapy devices, close collaboration with world-leading cancer centers and industrial partners, and extensive investment in research and development.
BUSINESS MODEL
RaySearch's main revenue is generated by customers paying an initial license fee for the right to use RaySearch's software and an annually recurring service fee for access to updates and support. All software systems are developed at RaySearch's head office in Stockholm, and distributed and supported by the company's global marketing organization.
